Antibody Formulation Stability via Trehalose Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable aqueous pharmaceutical formulations of antibodies, such as anti-VEGF and anti-CD20 antibodies, that prevent the formation of dimers, soluble aggregates, and particulates, as existing formulations fail to adequately mitigate these issues.
Innovation Solution
A stable aqueous pharmaceutical formulation comprising a monoclonal antibody, trehalose, and a buffer, with a specific weight ratio of the antibody to trehalose between 1.65 and 4.95, and a pH of 5.5 to 6.5, including a surfactant like poloxamer 188, which maintains the antibody's stability and prevents aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional aqueous formulations are used for antibodies, then the formulations are easy to prepare and administer, but they fail to prevent protein aggregation, deamidation, and oxidation
Solution Approach 1:
The patent employs a composite formulation system combining multiple protective agents (trehalose, surfactants, buffers) with the antibody at specific concentration ratios. This composite approach creates synergistic protection against aggregation, deamidation, and oxidation that exceeds the capability of individual excipients, directly resolving the contradiction between stability and complexity by integrating multiple functional components into a unified stable system.
Solution Approach 2:
The patent optimizes critical formulation parameters including trehalose concentration (10-500 mM), buffer pH (5.0-7.0), ionic strength, and surfactant concentration (0.01-1%). By systematically adjusting these parameters to specific ranges, the formulation achieves maximum stability while avoiding conditions that promote degradation, thus resolving the contradiction between achieving high reliability and maintaining manageable complexity.
2Quantity of substance
If high concentrations of antibodies are formulated, then the therapeutic efficacy is improved, but the formation of dimers and soluble aggregates increases
Solution Approach 1:
The patent introduces trehalose as a molecular intermediary that mediates between antibody molecules at high concentrations. Trehalose forms a protective matrix around the antibodies and acts as a spacer that prevents direct antibody-antibody interactions leading to aggregation. This intermediary mechanism enables the formulation to maintain high antibody concentrations (improving therapeutic efficacy) while preventing dimer and soluble aggregate formation (maintaining stability).
Solution Approach 2:
The patent employs surfactants as sacrificial protective agents that preferentially interact with hydrophobic surfaces on antibody molecules. These surfactants form protective layers that prevent aggregation, and can be used in relatively high concentrations without compromising stability. The surfactants act as disposable protective elements that can be optimized at lower costs to enable high antibody concentration formulations without aggregation.
3Duration of action of stationary object
If lyophilization is used to stabilize the antibody, then the storage stability is improved, but the manufacturing process becomes more complex and time-consuming
Solution Approach 1:
The patent extracts and eliminates the need for lyophilization by developing a novel aqueous formulation system that provides equivalent or superior stability without the freezing and drying steps. By removing the lyophilization process entirely, the formulation achieves storage stability through chemical and physical stabilization mechanisms in the liquid state, significantly simplifying manufacturing while maintaining or improving storage stability.
Solution Approach 2:
Instead of using lyophilization (removing water to stabilize), the patent inverts the approach by optimizing the aqueous environment to stabilize the antibody in the liquid state. The formulation uses water as a stabilizing medium rather than a destabilizing factor, employing hydrophilic excipients like trehalose and optimized buffers to maintain antibody stability in aqueous solution, thereby eliminating the need for complex lyophilization processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively maintains the stability and biological activity of the monoclonal antibody, preventing aggregation and deamidation, and is stable for at least 6 months at -20°C, making it suitable for long-term storage and administration.
Implementation Method 1
A stable aqueous pharmaceutical formulation comprising a monoclonal antibody, trehalose and a buffer, wherein the weight ratio of the monoclonal antibody to the trehalose in the formulation is about 1.65 to about 4.95
Implementation Method 2
A stable aqueous pharmaceutical formulation comprising a monoclonal antibody, trehalose and a buffer, wherein the formulation has a pH of 5.5 to 6.5
Implementation Method 3
wherein the formulation comprises a surfactant in a concentration of 0.01 % to 0.1 %, wherein said surfactant is poloxamer 188
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a PH in the range of about 5.5 to about 7.10. The invention also provides methods for making such formulations and methods of using such formulations. In the past years, advances in biotechnology have made it possible to produce a variety of proteins for pharmaceutical applications using recombinant DNA techniques.